Published in Virology on April 10, 2004
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer (2009) 2.77
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A (2004) 2.43
In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe (2010) 2.24
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75
Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst (2011) 1.71
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis (2009) 1.70
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A (2006) 1.48
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother (2014) 1.48
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32
A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis (2011) 1.31
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol (2007) 1.23
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One (2013) 1.23
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
Large scale RNAi reveals the requirement of nuclear envelope breakdown for nuclear import of human papillomaviruses. PLoS Pathog (2014) 1.16
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12
Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol (2011) 1.11
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol (2006) 1.08
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine (2011) 1.07
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology (2007) 1.07
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol (2010) 1.05
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One (2010) 1.02
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One (2012) 1.01
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Asymptomatic primary Merkel cell polyomavirus infection among adults. Emerg Infect Dis (2011) 0.99
HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One (2013) 0.99
Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol (2004) 0.99
Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther (2012) 0.98
Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J (2006) 0.95
Role of L2 cysteines in papillomavirus infection and neutralization. Virol J (2009) 0.95
Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay. Clin Vaccine Immunol (2008) 0.94
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93
Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol (2009) 0.93
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol (2007) 0.92
Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol (2010) 0.92
Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol (2013) 0.90
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology (2013) 0.89
Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58. J Gen Virol (2010) 0.89
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol (2009) 0.89
BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism. J Virol (2013) 0.88
Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines (2013) 0.88
Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol (2014) 0.88
Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog (2012) 0.88
Polyethylenimine is a strong inhibitor of human papillomavirus and cytomegalovirus infection. Antimicrob Agents Chemother (2011) 0.88
Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol (2007) 0.88
Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. J Virol (2013) 0.87
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol (2007) 0.87
Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis (2014) 0.87
Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin Vaccine Immunol (2006) 0.87
Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine (2009) 0.86
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
Kallikrein-8 Proteolytically Processes Human Papillomaviruses in the Extracellular Space To Facilitate Entry into Host Cells. J Virol (2015) 0.85
An unbiased in vivo screen reveals multiple transcription factors that control HPV E6-regulated hTERT in keratinocytes. Virology (2013) 0.85
Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology (2015) 0.85
Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol (2008) 0.85
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother (2015) 0.85
Serodiagnosis for tumor viruses. Semin Oncol (2014) 0.85
The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. Virology (2011) 0.85
Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection. Antimicrob Agents Chemother (2014) 0.84
Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One (2013) 0.84
Oral human papillomavirus is common in individuals with Fanconi anemia. Cancer Epidemiol Biomarkers Prev (2015) 0.83
Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation. J Gen Virol (2011) 0.83
A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine (2010) 0.83
Differential binding patterns to host cells associated with particles of several human alphapapillomavirus types. J Gen Virol (2009) 0.82
Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. PLoS One (2014) 0.82
A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects. EBioMedicine (2016) 0.82
Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. Front Oncol (2014) 0.81
Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant (2013) 0.81
Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody. PLoS One (2015) 0.81
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine (2014) 0.81
Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol (2007) 0.81
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One (2014) 0.81
The CD63-Syntenin-1 Complex Controls Post-Endocytic Trafficking of Oncogenic Human Papillomaviruses. Sci Rep (2016) 0.81
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype. J Virol (2015) 0.79
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One (2015) 0.79
The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PLoS One (2012) 0.79
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine. Clin Vaccine Immunol (2014) 0.78
Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. Clin Vaccine Immunol (2012) 0.78
Immunizing against Anogenital Cancer: HPV Vaccines. PLoS Pathog (2016) 0.78
Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J Immunol Methods (2014) 0.78
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Comprehensive analysis of heterochromatin- and RNAi-mediated epigenetic control of the fission yeast genome. Nat Genet (2005) 4.66
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe (2010) 3.78
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis. Proc Natl Acad Sci U S A (2004) 3.31
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Maturation of papillomavirus capsids. J Virol (2005) 3.18
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer (2008) 3.16
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet (2005) 2.92
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer (2009) 2.77
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol (2010) 2.65
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A (2006) 2.64
Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol (2010) 2.61
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2003) 2.58
Papillomaviruses infect cells via a clathrin-dependent pathway. Virology (2003) 2.47
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A (2004) 2.43
E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J (2004) 2.38
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol (2007) 2.25
In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe (2010) 2.24
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis (2013) 2.18
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol (2006) 2.16
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog (2009) 2.08
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05
Taxonomical developments in the family Polyomaviridae. Arch Virol (2011) 2.03
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A (2009) 1.90